Exploring CRISPR Technology To Enhance Cancer Immunotherapy
New research has identified genetic modifications that may increase the effectiveness of immunotherapy for multiple myeloma, a difficult-to-treat blood cancer most often diagnosed in people over 65.
A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard used CRISPR technology to pinpoint genes that could be edited to boost the efficacy of chimeric antigen receptor (CAR) T-cell therapy for cancer.
When the researchers edited those genes, they found that some of the modifications improved T-cell function and survival in a lab dish and in a mouse model of multiple myeloma.
Comments
Post a Comment